SBU

Elekta AB (OTCMKTS:EKTAY - Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totaling 191 shares. Based on an average daily trading volume, of 2,905 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's stock are sold short.

Elekta Stock Up 0.2%

Shares of Elekta stock traded up $0.01 on Friday, hitting $5.92. 386 shares of the company's stock traded hands, compared to its average volume of 851. Elekta has a 52-week low of $4.35 and a 52-week high of $6.93. The company has a quick ratio of 0.62, a current ratio of 0.86 and a debt-to-equity ratio of 0.45. The stock has a market cap of $2.18 billion, a P/E ratio of -49.33 and a beta of 1.03. The firm's 50-day moving average is $5.41 and its 200 day moving average is $5.70.

Elekta (OTCMKTS:EKTAY - Get Free Report) last issued its quarterly earnings results on Thursday, August 27th. The company reported $0.07 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 2.38% and a positive return on equity of 13.47%. The business had revenue of $372.30 million during the quarter. Equities analysts anticipate that Elekta will post 0.43 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Elekta from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold".

Check Out Our Latest Report on EKTAY

About Elekta

(Get Free Report)

Elekta AB is a Sweden-based medical technology company that develops and supplies systems and software for radiation therapy, radiosurgery and related cancer-care applications. Its solutions are designed to help hospitals and clinics treat tumors while supporting more precise, personalized and less invasive care.

The company's portfolio includes linear accelerators, stereotactic radiosurgery systems, magnetic resonance-guided radiation therapy technology and brachytherapy products. Elekta also provides oncology information systems and workflow software, including platforms used for treatment planning, patient management and clinical data coordination.

Founded in 1972 by neurosurgeon and inventor Lars Leksell, Elekta initially focused on radiosurgery and later expanded into broader radiation oncology.

Featured Articles

• Five stocks we like better than Elekta
• Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
• 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
• Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
• Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elekta Right Now?

Before you consider Elekta, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta wasn't on the list.

While Elekta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here